■COVID-19是一种由严重急性呼吸道综合征冠状病毒2(SARS-CoV-2)感染引起的呼吸道疾病。血栓并发症在COVID-19患者中似乎特别重要。本研究旨在调查COVID-19患者3周内抗磷脂抗体(抗心磷脂和抗β2-糖蛋白-I)水平和血栓栓塞指数的变化。
这项横断面研究是对在伊斯法罕的Al-Zahra医院住院的Covid-19成人进行的。病例组包括入住内部病房或ICU的患者,尽管接受了预防性或抗凝血剂剂量,但仍有血栓并发症,对照组包括无血栓栓塞事件的COVID-19患者。考虑了120人的样本量。抗心磷脂和抗β2-糖蛋白-I抗体,凝血谱,包括纤维蛋白原,PTT,PT肌钙蛋白,ESR,CRP,检测D-二聚体。收集后,将数据输入spss24软件并进行分析.
■结果表明,IgM和IgG中抗心磷脂和抗β-2糖蛋白的变化以及ESR的变化无统计学意义,CRP,PTT,PT,两组纤维蛋白原水平比较(P>0.05)。
■我们的研究表明,抗磷脂抗体(抗心磷脂和抗β-2糖蛋白)与血栓栓塞事件之间没有统计学上的显着关系。因此,抗心磷脂和抗β-2糖蛋白可能是导致COVID-19患者血栓形成的难题,和其他炎症反应应检查病例。
UNASSIGNED: COVID-19 is a respiratory disease caused by infection with severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2). Thrombotic complications appear to be of particular importance in patients with COVID-19. This study aimed to investigate Changes in the level of Antiphospholipid antibodies (
Anticardiolipin and Anti-β2-glycoprotein-I) and thromboembolic indices in COVID-19 patients during 3 weeks.
UNASSIGNED: This cross-sectional study was performed on adults with Covid-19 hospitalized at Al-Zahra Hospital in Isfahan. The case group includes the patients admitted to the internal ward or ICU who despite receiving prophylactic or anticoagulant doses suffer from thrombotic complications and the control group includes COVID-19 patients without thromboembolic events. The sample size of 120 people was considered.
Anticardiolipin and anti-β2-glycoprotein-I antibodies, coagulation profiles including Fibrinogen, PTT, PT Troponin, ESR, CRP, and D-dimer were examined. After collection, the data were entered into spss24 software and analyzed.
UNASSIGNED: The results showed that there was no statistically significant difference in the changes of
anticardiolipin and anti-beta-2 glycoprotein in IgM and IgG as well as in the changes of ESR, CRP, PTT, PT, and fibrinogen in the two groups (P > 0.05).
UNASSIGNED: Our study showed that there was no statistically significant relationship between anti-phospholipid antibodies (
anticardiolipin and anti-beta-2 glycoprotein) and thromboembolic events. Therefore
anticardiolipin and anti-beta-2 glycoprotein is probably the puzzles causing thrombosis in COVID-19 patients, and other inflammatory responses should be examined among the cases.